InvestSMART

Global X S&P Biotech ETF (ASX: CURE) - Announcements

- Current share price for CURE : $57.230

Global X S&P Biotech ETF (CURE) is an Exchange Traded Fund - commonly known as an ETF. For more details about how ETFs work, feel free to check out our What is an ETF? overview. The Global X S&P Biotech ETF (CURE) seeks to invest in companies that stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.

Latest company announcements for Global X S&P Biotech ETF (CURE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$38 Annual Financial Report 20 Sep 2024 2:52PM $51.150 $57.230 risen by 11.89%
$38 PDS dated 16 September 2024 16 Sep 2024 5:11PM $51.730 $57.230 risen by 10.63%
$38 Global X Units on Issue - August 2024 6 Sep 2024 5:17PM $49.700 $57.230 risen by 15.15%
$38 Global X Units on Issue - July 2024 7 Aug 2024 9:23AM $49.460 $57.230 risen by 15.71%
$38 Global X Units on Issue - June 2024 4 Jul 2024 4:50PM n/a $57.230 n/a
$38 Global X Final Distribution Announcement - June 2024 2 Jul 2024 5:27PM n/a $57.230 n/a
$38 Global X Updated Est. Distribution Announcement - June 2024 28 Jun 2024 9:53AM $47.010 $57.230 risen by 21.74%
$38 Global X Estimated Distribution Announcement - June 2024 24 Jun 2024 7:25PM $47.330 $57.230 risen by 20.92%
$38 Global X Units on Issue - May 2024 6 Jun 2024 9:58AM $46.760 $57.230 risen by 22.39%
$38 Global X Units on Issue - April 2024 3 May 2024 4:54PM $45.790 $57.230 risen by 24.98%
$38 Global X Units on Issue - March 2024 3 Apr 2024 10:29AM $48.000 $57.230 risen by 19.23%
$38 Half Year Accounts 11 Mar 2024 4:17PM $50.800 $57.230 risen by 12.66%
$38 Global X Units on Issue - February 2024 4 Mar 2024 5:04PM $52.800 $57.230 risen by 8.39%
$38 Global X Updated Units on Issue - January 2024 2 Feb 2024 3:59PM $46.200 $57.230 risen by 23.87%
$38 Global X Units on Issue - January 2024 2 Feb 2024 3:39PM $46.200 $57.230 risen by 23.87%
$38 Global X Units on Issue - December 2023 3 Jan 2024 10:02AM $45.500 $57.230 risen by 25.78%
$38 Global X Units on Issue - November 2023 4 Dec 2023 10:09AM $39.380 $57.230 risen by 45.33%
$38 Global X Units on Issue - October 2023 6 Nov 2023 3:55PM $37.600 $57.230 risen by 52.21%
$38 Global X Units on Issue - September 2023 3 Oct 2023 4:14PM $38.100 $57.230 risen by 50.21%
$38 CURE Annual Financial Report 21 Sep 2023 8:48AM $40.150 $57.230 risen by 42.54%
$38 Global X Units on Issue - August 2023 4 Sep 2023 9:36AM $41.890 $57.230 risen by 36.62%
$38 PDS dated 4 August 2023 9 Aug 2023 4:18PM $41.820 $57.230 risen by 36.85%
$38 Global X Units on Issue July 2023 3 Aug 2023 8:39AM $43.230 $57.230 risen by 32.38%
$38 Global X Units on Issue June 2023 11 Jul 2023 10:31AM $42.930 $57.230 risen by 33.31%
$38 Global X Final Distribution Announcement - June 2023 4 Jul 2023 4:29PM $42.570 $57.230 risen by 34.44%

26 - 50 of 118 results

Page 2 of 5

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.